Edition:
United States

Orexo AB (ORX.ST)

ORX.ST on Stockholm Stock Exchange

31.30SEK
24 Feb 2017
Change (% chg)

0.30kr (+0.97%)
Prev Close
31.00kr
Open
31.00kr
Day's High
31.60kr
Day's Low
30.90kr
Volume
69,296
Avg. Vol
146,564
52-wk High
63.00kr
52-wk Low
30.80kr

ORX.ST

Chart for ORX.ST

About

Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects... (more)

Overall

Beta: 1.63
Market Cap(Mil.): kr1,081.09
Shares Outstanding(Mil.): 34.54
Dividend: --
Yield (%): --

Financials

  ORX.ST Industry Sector
P/E (TTM): 27.23 28.84 29.63
EPS (TTM): 1.15 -- --
ROI: 5.37 13.44 12.96
ROE: 13.71 14.34 14.11

BRIEF-Orexo completes bond buyback program

* Says has successfully completed a limited bond buyback program and in total purchased Orexo corporate bonds in the market with a nominal value of MSEK 59 Source text for Eikon: Further company coverage: (Stockholm Newsroom)

Feb 20 2017

BRIEF-Orexo swings to net profit in Q4

* Q4 net earnings msek 33.3 (-51.8) Source text for Eikon: Further company coverage: (Stockholm Newsroom)

Jan 26 2017

Orexo, Actavis split win on Zubsolv patents

A split patent decision by a federal judge in Delaware will allow Swedish pharmaceutical firm Orexo AB and its U.S. subsidiary to hold off generic competition to its opioid-addiction drug Zubsolv for three more years, but not the 16 years the company sought.

Nov 17 2016

BRIEF-Orexo says may appeal part of U.S. patent ruling

* Favorable outcome from Zubsolv patent infringement litigation against Actavis

Nov 16 2016

BRIEF-Orexo Q3 net earnings 36.0 mln crowns

* Says our ambition is to win a disproportionate share of new patients in regions where Zubsolv is reimbursed and have market access comparable to our main branded competitors

Oct 20 2016

BRIEF-U.S. FDA approves Orexo's low dose Zubsolv for treatment of patients with opioid dependence

* U.S. FDA approves Orexo's low dose zubsolv buprenorphine and naloxone sublingual tablets (CIII)

Oct 06 2016

BRIEF-Orexo says receives FDA approval for Zubsolv

* Says it has received approval from the US Food and Drug Administration (FDA) of a new unique low dose, 0.7mg/0.18 mg, tablet of Zubsolv (buprenorphine/naloxone) sublingual tablet (CIII) for the treatment of opioid dependence

Oct 06 2016

More From Around the Web

Earnings vs. Estimates